AI-driven epitope screening accelerates vaccine design but risks reinforcing extractive biomedical paradigms over systemic immune health solutions
Original framing: “What this AI epitope library means for vaccines, immunotherapy and biosensors” — Phys.org
Epitope screening is grounded in immunogenetics, where specific protein fragments (epitopes) are recognized by immune cells to trigger responses. Machine learning accelerates epitope discovery by predicting binding affinities, reducing trial-and-error in vaccine design. However, the scientific community has raised concerns about the oversimplification of immune responses, as epitopes are part of complex, dynamic networks. The epiGPTope system's reliance on synthetic data may also introduce biases, as training datasets often lack diversity in global immune profiles.
The epiGPTope system exemplifies the tension between technological innovation and systemic inequity in global health, where AI-driven epitope screening is framed as a neutral tool but serves to reinforce extractive biomedical paradigms.
Historically, vaccine development has been marred by ethical failures, such as the Tuskegee experiments, and the current focus on synthetic epitope optimization risks repeating these mistakes by prioritizing corporate interests over public health. Cross-culturally, immune health is understood as a dynamic interplay of environmental, spiritual, and communal factors, yet the epiGPTope narrative sidelines this wisdom in favor of reductionist, Western biomedical models. The solution lies in decolonizing epitope research by integrating indigenous knowledge, democratizing access to AI tools, and adopting holistic immune health frameworks that account for marginalized perspectives. Without these systemic shifts, epitope screening will remain a tool of inequity rather than a pathway to global health justice.